Drug Trial News

RSS

Trial of three vaccines for Zaire Ebola virus disease

Researchers perform two randomized controlled trials to determine immunogenicity and safety of three Ebola vaccines.

20 Dec 2022

CU study proves effectiveness of new multidrug treatment for patients with stage IV melanoma

A new multidrug treatment for patients with stage IV melanoma has proven effective after a three-year clinical trial at the University of Colorado Cancer Center.

16 Dec 2022

Trial results confirm the safety of three different Ebola vaccine regimens

Ebola epidemics occur periodically in various sub-Saharan African countries. While vaccines exist and have already received WHO Prequalification against the Zaire ebolavirus species, it is essential to pursue and intensify efforts to supplement the available data to develop a safe and effective Ebola vaccine strategies in adults and children alike.

16 Dec 2022

Randomized trials demonstrate the safety of Ebola vaccine regimens in adults and children

Two randomized, placebo-controlled trials evaluating three Ebola vaccine administration strategies in adults and children found that all the regimens were safe in both age groups, according to results published today in the New England Journal of Medicine.

15 Dec 2022

No benefit of low dose apixaban following acute COVID-19

The HEAL-COVID trial compared the efficacy of Apixaban to standard care in adults who have recently recovered from severe COVID-19.

14 Dec 2022

Updated guidelines seek to improve transparency and utility in clinical trial reporting

In a global study of outcome reporting in clinical trials, a research team at The Hospital for Sick Children (SickKids) has issued updated guidelines on what should be included in all trial protocols and published clinical trial reports, with the goal to improve their transparency and utility.

14 Dec 2022

Major treatment advance revealed for adults with newly diagnosed B lineage acute lymphoblastic leukemia

Late-breaking research reveals a major treatment advance for adults with newly diagnosed B lineage acute lymphoblastic leukemia (ALL).

14 Dec 2022

Obesity and type 2 diabetes impair mRNA COVID vaccine efficacy in mouse model

In a recent study posted to bioRxiv*, researchers in the United States assessed the impact of metabolic diseases on coronavirus disease 2019 (COVID-19) vaccine immunogenicity in a mouse model.

13 Dec 2022

Targeted therapies and novel drug combinations show promise for the treatment of multiple leukemias

Researchers from The University of Texas MD Anderson Cancer Center are presenting compelling findings from three clinical trials at the 2022 American Society of Hematology Annual Meeting.

13 Dec 2022

Novel drug shows early potential in combating multiple myeloma

A first-of-its-kind drug known as modakafusp alfa has shown early potential in combating multiple myeloma, a form of bone marrow cancer, in a study presented by researchers from the University of Pennsylvania's Abramson Cancer Center at the 2022 American Society of Hematology Annual Meeting (Abstract 565).

12 Dec 2022

Simplified treatment regimen results in dramatic decrease in early deaths from acute promyelocytic leukemia

The use of a simplified treatment regimen by oncologists, along with management recommendations and 24/7 support provided by a limited and dedicated group of academic disease experts, resulted in a dramatic decrease in early deaths from acute promyelocytic leukemia (APL).

12 Dec 2022

Three-drug combination highly effective in patients with high-risk forms of chronic lymphocytic leukemia

A three-drug combination that sent chronic lymphocytic leukemia (CLL) into deep remissions in a broad group of patients in a clinical trial is highly effective in patients with high-risk forms of the disease, a new, phase 2 clinical trial led by Dana-Farber Cancer Institute investigators indicates.

12 Dec 2022

$Forxiga (dapagliflozin) approved in Great Britain for symptomatic chronic heat failure across the full spectrum of left ventricular ejection fraction$

Forxiga (dapagliflozin) approved in Great Britain for symptomatic chronic heat failure across the full spectrum of left ventricular ejection fraction

AstraZeneca today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a licence extension for dapagliflozin in Great Britain for the treatment of symptomatic chronic heart failure (HF) in patients with HF and a left ventricular ejection fraction (LVEF) >40%, including HF with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF).

From AstraZeneca 12 Dec 2022

Ongoing Phase I clinical trial demonstrates successful re-treatment with CAR T cell therapy

Researchers from the University of Pennsylvania's Abramson Cancer Center presented preliminary results of an ongoing Phase I clinical trial demonstrating successful re-treatment with CAR T cell therapy for patients whose cancers relapsed after previous CAR T therapy at the 2022 American Society of Hematology Annual Meeting.

12 Dec 2022

Off-the-shelf immunotherapy could offer new hope for patients with hard-to-treat multiple myeloma

A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73 percent of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.

12 Dec 2022

Study shows potential benefits of efgartigimod as a treatment for immune thrombocytopenia

Patients taking efgartigimod, a drug being studied for use to treat chronic primary immune thrombocytopenia (ITP), exhibited a significantly greater improvement in platelet counts which are essential to clotting and stopping bleeding, compared to those taking a placebo, according to results reported from the ADVANCE IV clinical trial, which was conducted globally, including at Georgetown University Medical Center.

12 Dec 2022

Intranasal recombinant MVA-based vaccines effective against SARS-CoV-2 variants in mice

Researchers construct a recombinant host-range restricted vaccinia virus Ankara (rMVAs) expressing the spike proteins of several SARS-CoV-2 variants.

11 Dec 2022

Addition of capivasertib to fulvestrant doubles progression-free survival in HR-positive breast cancer patients

In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled the median progression-free survival compared with placebo plus fulvestrant in the phase III CAPItello-291 clinical trial, according to results presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

9 Dec 2022

Multi-stage HIV vaccine regimen shows promising results in Phase 1 clinical trial

The George Washington University Vaccine Research Unit in partnership with Scripps Research, IAVI, Fred Hutchinson Cancer Center (FHCC) and the National Institutes of Health, National Institute of Allergy and Infectious Diseases Vaccine Research Center published the results of their Phase 1 Clinical Trial in Science.

8 Dec 2022

Updated results on a new approach to treating advanced ER-positive/HER2-negative breast cancer

A UCLA Jonsson Comprehensive Cancer Center researcher and collaborators in a multicenter study will present updated results and plans for further research on a new approach to treating advanced ER-positive/HER2-negative breast cancer.

7 Dec 2022

Previous
1
...
25
26
27
28
29
30
31
...
1143
Next

Drug Trial News

Trial of three vaccines for Zaire Ebola virus disease

CU study proves effectiveness of new multidrug treatment for patients with stage IV melanoma

Trial results confirm the safety of three different Ebola vaccine regimens

Randomized trials demonstrate the safety of Ebola vaccine regimens in adults and children

No benefit of low dose apixaban following acute COVID-19

Updated guidelines seek to improve transparency and utility in clinical trial reporting

Major treatment advance revealed for adults with newly diagnosed B lineage acute lymphoblastic leukemia

Obesity and type 2 diabetes impair mRNA COVID vaccine efficacy in mouse model

Targeted therapies and novel drug combinations show promise for the treatment of multiple leukemias

Novel drug shows early potential in combating multiple myeloma

Simplified treatment regimen results in dramatic decrease in early deaths from acute promyelocytic leukemia

Three-drug combination highly effective in patients with high-risk forms of chronic lymphocytic leukemia

Forxiga (dapagliflozin) approved in Great Britain for symptomatic chronic heat failure across the full spectrum of left ventricular ejection fraction

Ongoing Phase I clinical trial demonstrates successful re-treatment with CAR T cell therapy

Off-the-shelf immunotherapy could offer new hope for patients with hard-to-treat multiple myeloma

Study shows potential benefits of efgartigimod as a treatment for immune thrombocytopenia

Intranasal recombinant MVA-based vaccines effective against SARS-CoV-2 variants in mice

Addition of capivasertib to fulvestrant doubles progression-free survival in HR-positive breast cancer patients

Multi-stage HIV vaccine regimen shows promising results in Phase 1 clinical trial

Updated results on a new approach to treating advanced ER-positive/HER2-negative breast cancer

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News